{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:13:21Z","timestamp":1758633201754},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00105-021-04849-7","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T08:10:51Z","timestamp":1625472651000},"page":"676-685","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Lokale und neue apparative Therapien der milden Hidradenitis suppurativa"],"prefix":"10.1007","volume":"72","author":[{"given":"G.","family":"Nikolakis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"von Stebut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"4849_CR1","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/jdv.15332","volume":"33","author":"V Bettoli","year":"2019","unstructured":"Bettoli\u00a0V, Manfredini\u00a0M, Massoli\u00a0L et\u00a0al (2019) Rates of antibiotic resistance\/sensitivity in bacterial cultures of hidradenitis suppurativa patients. J\u00a0Eur Acad Dermatol Venereol 33:930\u2013936. https:\/\/doi.org\/10.1111\/jdv.15332","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4849_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2340\/00015555-3558","volume":"100","author":"IJ Bisschoff","year":"2020","unstructured":"Bisschoff\u00a0IJ, Kasche\u00a0D, Kirschner\u00a0U et\u00a0al (2020) Laight\u00ae therapy improves hidradenitis suppurativa in patients declining surgical intervention: two case reports. Acta Derm Venereol 100:1\u20132. https:\/\/doi.org\/10.2340\/00015555-3558","journal-title":"Acta Derm Venereol"},{"key":"4849_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1365-2230.2009.03377.x","volume":"35","author":"J Boer","year":"2010","unstructured":"Boer\u00a0J, Jemec\u00a0GBE (2010) Resorcinol peels as a\u00a0possible self-treatment of painful nodules in hidradenitis suppurativa. Clin Exp Dermatol 35:36\u201340. https:\/\/doi.org\/10.1111\/j.1365-2230.2009.03377.x","journal-title":"Clin Exp Dermatol"},{"key":"4849_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1468-3083.1999.tb00838.x","volume":"13","author":"N Cassano","year":"1999","unstructured":"Cassano\u00a0N, Alessandrini\u00a0G, Mastrolonardo\u00a0M, Vena\u00a0GA (1999) Peeling agents: toxicological and allergological aspects. J\u00a0Eur Acad Dermatol Venereol 13:14\u201323. https:\/\/doi.org\/10.1111\/j.1468-3083.1999.tb00838.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4849_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1365-4362.1983.tb02150.x","volume":"22","author":"OJ Clemmensen","year":"1983","unstructured":"Clemmensen\u00a0OJ (1983) Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol 22:325\u2013328. https:\/\/doi.org\/10.1111\/j.1365-4362.1983.tb02150.x","journal-title":"Int J Dermatol"},{"key":"4849_CR6","doi-asserted-by":"publisher","DOI":"10.1159\/000515450","author":"A Docampo-Sim\u00f3n","year":"2021","unstructured":"Docampo-Sim\u00f3n\u00a0A, Beltr\u00e1-Pic\u00f3\u00a0I, S\u00e1nchez-Pujol\u00a0MJ et al (2021) Topical 15\u202f% resorcinol is associated with high treatment satisfaction in patients with mild to moderate hidradenitis suppurativa. Dermatology. https:\/\/doi.org\/10.1159\/000515450","journal-title":"Dermatology"},{"key":"4849_CR7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1365-2230.1995.tb01351.x","volume":"20","author":"A Firooz","year":"1995","unstructured":"Firooz\u00a0A, Tehranchi-Nia\u00a0Z, Ahmed\u00a0AR (1995) Benefits and risks of intralesional corticosteroid injection in the treatment of dermatological diseases. Clin Exp Dermatol 20:363\u2013370. https:\/\/doi.org\/10.1111\/j.1365-2230.1995.tb01351.x","journal-title":"Clin Exp Dermatol"},{"key":"4849_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jaad.2016.08.001","volume":"76","author":"AH Fischer","year":"2017","unstructured":"Fischer\u00a0AH, Haskin\u00a0A, Okoye\u00a0GA (2017) Patterns of antimicrobial resistance in lesions of hidradenitis suppurativa. J\u00a0Am Acad Dermatol 76:309\u2013313.e2. https:\/\/doi.org\/10.1016\/j.jaad.2016.08.001","journal-title":"J Am Acad Dermatol"},{"key":"4849_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1655524","author":"FJ Garc\u00eda-Mart\u00ednez","year":"2019","unstructured":"Garc\u00eda-Mart\u00ednez\u00a0FJ, Vilarrasa Rull\u00a0E, Salgado-Boquete\u00a0L et al (2019) Intralesional corticosteroid injection for the treatment of hidradenitis suppurativa: a\u00a0multicenter retrospective clinical study. J\u00a0Dermatolog Treat. https:\/\/doi.org\/10.1080\/09546634.2019.1655524","journal-title":"J Dermatolog Treat"},{"key":"4849_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-016-9328-5","author":"W Gulliver","year":"2016","unstructured":"Gulliver\u00a0W, Zouboulis\u00a0CC, Prens\u00a0E et al (2016) Evidence-based approach to the treatment of hidradenitis suppurativa\/acne inversa, based on the European guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord. https:\/\/doi.org\/10.1007\/s11154-016-9328-5","journal-title":"Rev Endocr Metab Disord"},{"key":"4849_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1524-4725.2007.34025.x","volume":"34","author":"J Iwasaki","year":"2008","unstructured":"Iwasaki\u00a0J, Marra\u00a0DE, Fincher\u00a0EF, Moy\u00a0RL (2008) Treatment of hidradenitis suppurativa with a\u00a0nonablative radiofrequency device. Dermatol Surg 34:114\u2013117. https:\/\/doi.org\/10.1111\/j.1524-4725.2007.34025.x","journal-title":"Dermatol Surg"},{"key":"4849_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-33101-8","volume-title":"Hidradenitis suppurativa","author":"GBE Jemec","year":"2006","unstructured":"Jemec\u00a0GBE, Revuz\u00a0J, Leyden\u00a0JJ (2006) Hidradenitis suppurativa https:\/\/doi.org\/10.1007\/978-3-540-33101-8"},{"key":"4849_CR13","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0190-9622(98)70272-5","volume":"39","author":"GBE Jemec","year":"1998","unstructured":"Jemec\u00a0GBE, Wendelboe\u00a0P (1998) Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J\u00a0Am Acad Dermatol 39:971\u2013974. https:\/\/doi.org\/10.1016\/S0190-9622(98)70272-5","journal-title":"J Am Acad Dermatol"},{"key":"4849_CR14","doi-asserted-by":"publisher","first-page":"e211677","DOI":"10.1001\/jamadermatol.2021.1677","volume":"2021 May 26","author":"A Jfri","year":"2021","unstructured":"Jfri\u00a0A, Nassim\u00a0D, O\u2019Brien\u00a0E, Gulliver\u00a0W, Nikolakis\u00a0G, Zouboulis\u00a0CC (2021) Prevalence of Hidradenitis Suppurativa: A Systematic Review and Meta-regression Analysis. JAMA Dermatol 2021 May 26:e211677. https:\/\/doi.org\/10.1001\/jamadermatol.2021.1677. Online ahead of print. PMID: 34037678","journal-title":"JAMA Dermatol"},{"key":"4849_CR15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1524-4725.2009.01380.x","volume":"36","author":"S Kawana","year":"2010","unstructured":"Kawana\u00a0S, Tachihara\u00a0R, Kato\u00a0T, Omi\u00a0T (2010) Effect of smooth pulsed light at 400 to 700 and 870 to 1,200\u202fnm for acne vulgaris in Asian skin. Dermatol Surg 36:52\u201357. https:\/\/doi.org\/10.1111\/j.1524-4725.2009.01380.x","journal-title":"Dermatol Surg"},{"key":"4849_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4103\/jdds.jdds_36_19","volume":"24","author":"U Kirschner","year":"2020","unstructured":"Kirschner\u00a0U, Lang\u00a0BM, Steinbrink\u00a0K, Zimmer\u00a0S (2020) Effectiveness of adalimumab in combination with intense pulsed light and radiofrequency therapy (LAight\u00ae) for severe hidradenitis suppurativa: A case report. J\u00a0Dermatol Dermatol Surg 24:133. https:\/\/doi.org\/10.4103\/jdds.jdds_36_19","journal-title":"J Dermatol Dermatol Surg"},{"key":"4849_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00491-1","author":"AB Lyons","year":"2019","unstructured":"Lyons\u00a0AB, Townsend\u00a0SM, Turk\u00a0D et al (2019) Laser and light-based treatment modalities for the management of hidradenitis suppurativa. Am J Clin Dermatol. https:\/\/doi.org\/10.1007\/s40257-019-00491-1","journal-title":"Am J Clin Dermatol"},{"key":"4849_CR18","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1111\/bjd.19337","volume":"183","author":"E Molinelli","year":"2020","unstructured":"Molinelli\u00a0E, Brisigotti\u00a0V, Simonetti\u00a0O et al (2020) Efficacy and safety of topical resorcinol 15\u202f% as long-term treatment of mild-to-moderate hidradenitis suppurativa: a\u00a0valid alternative to clindamycin in the panorama of antibiotic resistance. Br J Dermatol 183:1117\u20131119. https:\/\/doi.org\/10.1111\/bjd.19337","journal-title":"Br J Dermatol"},{"key":"4849_CR19","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.jaad.2017.07.008","volume":"77","author":"JC Pascual","year":"2017","unstructured":"Pascual\u00a0JC, Encabo\u00a0B, Ruiz de Apodaca\u00a0RF et al (2017) Topical 15\u202f% resorcinol for hidradenitis suppurativa: an uncontrolled prospective trial with clinical and ultrasonographic follow-up. J\u00a0Am Acad Dermatol 77:1175\u20131178. https:\/\/doi.org\/10.1016\/j.jaad.2017.07.008","journal-title":"J Am Acad Dermatol"},{"key":"4849_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1086\/426545","volume":"40","author":"TR Pasquale","year":"2005","unstructured":"Pasquale\u00a0TR, Tan\u00a0JS (2005) Nonantimicrobial effects of antibacterial agents. Clin Infect Dis 40:127\u2013135. https:\/\/doi.org\/10.1086\/426545","journal-title":"Clin Infect Dis"},{"key":"4849_CR21","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.jaad.2016.06.049","volume":"75","author":"PT Riis","year":"2016","unstructured":"Riis\u00a0PT, Boer\u00a0J, Prens\u00a0EP et\u00a0al (2016) Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): a case series. J\u00a0Am Acad Dermatol 75:1151\u20131155. https:\/\/doi.org\/10.1016\/j.jaad.2016.06.049","journal-title":"J Am Acad Dermatol"},{"key":"4849_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0149-1","author":"R Sabat","year":"2020","unstructured":"Sabat\u00a0R, Jemec\u00a0GBE, Matusiak \u0141 et\u00a0al (2020) Hidradenitis suppurativa. Nat Rev Dis Primers. https:\/\/doi.org\/10.1038\/s41572-020-0149-1","journal-title":"Nat. Rev. Dis. Primers"},{"key":"4849_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/annonc\/mds517","volume":"19","author":"N Scheinfeld","year":"2013","unstructured":"Scheinfeld\u00a0N (2013) Hidradenitis suppurativa: a practical review of possible medical treatments based on over 350 hidradenitis patients. Dermatol Online\u00a0J 19:1. https:\/\/doi.org\/10.1093\/annonc\/mds517","journal-title":"Dermatol Online J"},{"key":"4849_CR24","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jaad.2014.04.001","volume":"71","author":"AMR Schrader","year":"2014","unstructured":"Schrader\u00a0AMR, Deckers\u00a0IE, Van Der Zee\u00a0HH et\u00a0al (2014) Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity. J\u00a0Am Acad Dermatol 71:460\u2013467. https:\/\/doi.org\/10.1016\/j.jaad.2014.04.001","journal-title":"J Am Acad Dermatol"},{"key":"4849_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/clinpract11010005","volume":"11","author":"M Schultheis","year":"2021","unstructured":"Schultheis\u00a0M, Scheuern\u00a0M, Radkov\u00a0I (2021) Combining deroofing with LAight\u00ae therapy for long-term disease control of Hurley stage II hidradenitis suppurativa: case report. Clin Pract 11:26\u201331. https:\/\/doi.org\/10.3390\/clinpract11010005","journal-title":"Clin Pract"},{"key":"4849_CR26","doi-asserted-by":"crossref","unstructured":"Schultheis\u00a0M, Staubach\u00a0P, Nikolakis\u00a0G et\u00a0al (2021) LAight therapy significantly enhances treatment efficacy of topical clindamycin solution in Hurley I and II hidradenitis suppurativa: results from RELIEVE, a\u00a0multicenter randomized, blinded, controlled trial. Dermatology. (in press)","DOI":"10.1159\/000518540"},{"key":"4849_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41322-x","author":"J Seok","year":"2019","unstructured":"Seok\u00a0J, Kim\u00a0JH, Kim\u00a0JM et al (2019) Effects of intradermal radiofrequency treatment and intense pulsed light therapy in an acne-induced rabbit ear model. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-019-41322-x","journal-title":"Sci Rep"},{"key":"4849_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0065-2164(04)56004-5","volume":"56","author":"J Sp\u00ed\u017eek","year":"2004","unstructured":"Sp\u00ed\u017eek\u00a0J, Novotn\u00e1\u00a0J, \u0158ezanka\u00a0T (2004) Lincosamides: chemical structure, biosynthesis, mechanism of action, resistance, and applications. Adv Appl Microbiol 56:121\u2013154. https:\/\/doi.org\/10.1016\/S0065-2164(04)56004-5","journal-title":"Adv Appl Microbiol"},{"key":"4849_CR29","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/09546634.2017.1387226","volume":"29","author":"P Theut Riis","year":"2018","unstructured":"Theut Riis\u00a0P, Saunte\u00a0DM, Sigsgaard\u00a0V et\u00a0al (2018) Intense pulsed light treatment for patients with hidradenitis suppurativa: beware treatment with resorcinol. J\u00a0Dermatolog Treat 29:385\u2013387. https:\/\/doi.org\/10.1080\/09546634.2017.1387226","journal-title":"J Dermatolog Treat"},{"key":"4849_CR30","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1159\/000491547","volume":"234","author":"AMJD Vanlaerhoven","year":"2018","unstructured":"Vanlaerhoven\u00a0AMJD, Ardon\u00a0CB, Van Straalen\u00a0KR et\u00a0al (2018) Hurley III hidradenitis suppurativa has an aggressive disease course. Dermatology 234:232\u2013233. https:\/\/doi.org\/10.1159\/000491547","journal-title":"Dermatology"},{"key":"4849_CR31","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1677842","author":"S Wilden","year":"2019","unstructured":"Wilden\u00a0S, Friis\u00a0M, Tuettenberg\u00a0A et\u00a0al (2019) Combined treatment of hidradenitis suppurativa with intense pulsed light (IPL) and radiofrequency (RF). J\u00a0Dermatolog Treat. https:\/\/doi.org\/10.1080\/09546634.2019.1677842","journal-title":"J Dermatolog Treat"},{"key":"4849_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2012.08006.x","author":"CC Zouboulis","year":"2012","unstructured":"Zouboulis\u00a0CC, Bechara\u00a0FG, Fritz\u00a0K et al (2012) S1-Leitlinie zur Therapie der Hidradenitis suppurativa\/Acne inversa * (ICD-10 Ziffer: L73.2). J\u00a0Ger Soc Dermatol. https:\/\/doi.org\/10.1111\/j.1610-0387.2012.08006.x","journal-title":"J Ger Soc Dermatol"},{"key":"4849_CR33","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jdv.12966","volume":"29","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis\u00a0CC, Desai\u00a0N, Emtestam\u00a0L et\u00a0al (2015) European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa. J\u00a0Eur Acad Dermatol Venereol 29:619\u2013644. https:\/\/doi.org\/10.1111\/jdv.12966","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4849_CR34","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000431175","volume":"231","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis\u00a0CC, Del Marmol\u00a0V, Mrowietz\u00a0U et\u00a0al (2015) Hidradenitis suppurativa\/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology 231:184\u2013190. https:\/\/doi.org\/10.1159\/000431175","journal-title":"Dermatology"},{"key":"4849_CR35","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/bjd.15748","volume":"177","author":"CC Zouboulis Id","year":"2017","unstructured":"Zouboulis Id\u00a0CC, Tzellos\u00a0T, Kyrgidis\u00a0A et\u00a0al (2017) Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a\u00a0novel dynamic scoring system to assess HS severity. Br J Dermatol 177:1401\u20131409. https:\/\/doi.org\/10.1111\/bjd.15748","journal-title":"Br J Dermatol"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04849-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-021-04849-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04849-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T20:37:10Z","timestamp":1672691830000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-021-04849-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["4849"],"URL":"https:\/\/doi.org\/10.1007\/s00105-021-04849-7","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"assertion":[{"value":"25 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"G.\u00a0Nikolakis gibt an, dass kein Interessenkonflikt besteht. E.\u00a0von Stebut hat Berater- und Vortragshonorare von Almirall, InfectoPharm, Janssen, Leo Pharma, und Novartis erhalten, die nicht mit diesem Manuskript in Verbindung stehen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}